Exploring molecular genetics and gene editing approaches of peripheral neuropathies: A future treatment approach

Peripheral neuropathies are conditions in which the nerves of the peripheral nervous system (PNS) become disrupted. A tingling sensation and apathy are frequent symptoms. These symptoms could be unpleasant and are usually followed by fatigue. The hallmarks of acquired peripheral neuropathy (APN) include metabolic issues, inflammatory reactions, and impairments in axonal communication. Presently, it is known that errors in genetic material that encode proteins with a wide variety of activities result in different forms of Charcot-Marie-Tooth diseases (CMT) and associated hereditary peripheral neuropathies. Among these are cytoskeletal proteins, adhesion molecules, gap-junction proteins, transcription factors, receptors for neurotropic factors, structural proteins related to forming compact myelin, proteins involved in signalling pathways, and proteins involved in concealing the cell division process. The prospects of developing effective medications for neuropathic pain depend on the potential to comprehend pain mechanisms. Molecular methods for treating neuropathic pain include RNAi and gene-based therapies. New methods of gene therapy for the management of Inherited peripheral neuropathic conditions have been made possible by the latest innovations in genetic modification technologies. Driven by both inherited and acquired causes, the increasing frequency of peripheral neuropathies calls for creative and exact molecular therapies. This study is particularly relevant as direct manipulation of neuropathy-related mutations made possible by modern gene editing technologies like CRISPR-Cas9 and prime editing now helps Development of next-generation treatments depends on an awareness of these techniques.